Drug to reduce swelling in donor lungs for transplant
Treatments studied
Part of Immune system & allergy, Lungs & breathing clinical trials.
This trial tests whether giving a drug that blocks a protein called IL-1 (which causes inflammation and fluid buildup) can reduce swelling in donor lungs before they are transplanted. If you are getting a lung transplant and your donated lung is treated with a special machine, this study may help improve the lung's condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must be scheduled to receive a lung transplant.
- The donor lung must be treated with a special machine (ex vivo lung perfusion) before your transplant.
- You should not have used any IL-1 blocking medication before.
- You should not need a multi-organ transplant or a second transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests whether blocking a specific inflammation signal (TNF-alpha) can help prevent or improve kidney problems and early graft (new lung) dysfunction after a lung transplant at Northwestern. You might be eligible if you’re scheduled for that transplant and are willing to go through study consent and follow-up.
This trial tests whether a medicine called anakinra, which reduces inflammation, can prevent blood clots forming in the kidney after a transplant. It may help improve the chances of the new kidney working well.
This trial tests an immune-suppressing medicine to stop a serious complication called primary graft dysfunction that can happen soon after a lung transplant. It may help people who are already on the transplant waiting list and plan to receive a standard anti-rejection drug regimen.
This trial tests a drug called emapalumab for people who have a sudden drop in lung function after a lung transplant. The drug targets a protein that may be causing the damage, and the goal is to treat this reaction safely.
This study tests whether the drug tocilizumab can help prevent your body from rejecting a new lung after transplant. It might help improve the success of your transplant by reducing immune system activity.
This Phase 3 trial tests ARINA-1 to slow or prevent worsening lung transplant scarring in the breathing tubes (bronchiolitis obliterans). It may help people who are showing early decline in lung function but are not yet at advanced disease.
Hear when a new Lung Transplant Recipient trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.